Portal de Periódicos da CAPES

Current therapies for wound healing: electrical stimulation, biological therapeutics, and the potential for gene therapy

1999; Wiley; Volume: 38; Issue: 11 Linguagem: Inglês

10.1046/j.1365-4362.1999.00832.x

1365-4632

Martin Braddock, Callum J. Campbell, Daniel Züder,

Electrospun Nanofibers in Biomedical Applications

International Journal of DermatologyVolume 38, Issue 11 p. 808-817 Current therapies for wound healing: electrical stimulation, biological therapeutics, and the potential for gene therapy Martin Braddock BSc, PhD, Martin Braddock BSc, PhD Wound Healing and Tissue Regeneration Programme, Endothelial Gene Expression Group, Vascular Diseases Unit, Glaxo–Wellcome Medicines Research Centre, Stevenage, Hertfordshire, UK, and Department of Dermatology, University Hospital, Tuebingen, GermanySearch for more papers by this authorCallum J. Campbell BSc, PhD, Callum J. Campbell BSc, PhD Wound Healing and Tissue Regeneration Programme, Endothelial Gene Expression Group, Vascular Diseases Unit, Glaxo–Wellcome Medicines Research Centre, Stevenage, Hertfordshire, UK, and Department of Dermatology, University Hospital, Tuebingen, GermanySearch for more papers by this authorDaniel Zuder MD, Daniel Zuder MD Wound Healing and Tissue Regeneration Programme, Endothelial Gene Expression Group, Vascular Diseases Unit, Glaxo–Wellcome Medicines Research Centre, Stevenage, Hertfordshire, UK, and Department of Dermatology, University Hospital, Tuebingen, GermanySearch for more papers by this author Martin Braddock BSc, PhD, Martin Braddock BSc, PhD Wound Healing and Tissue Regeneration Programme, Endothelial Gene Expression Group, Vascular Diseases Unit, Glaxo–Wellcome Medicines Research Centre, Stevenage, Hertfordshire, UK, and Department of Dermatology, University Hospital, Tuebingen, GermanySearch for more papers by this authorCallum J. Campbell BSc, PhD, Callum J. Campbell BSc, PhD Wound Healing and Tissue Regeneration Programme, Endothelial Gene Expression Group, Vascular Diseases Unit, Glaxo–Wellcome Medicines Research Centre, Stevenage, Hertfordshire, UK, and Department of Dermatology, University Hospital, Tuebingen, GermanySearch for more papers by this authorDaniel Zuder MD, Daniel Zuder MD Wound Healing and Tissue Regeneration Programme, Endothelial Gene Expression Group, Vascular Diseases Unit, Glaxo–Wellcome Medicines Research Centre, Stevenage, Hertfordshire, UK, and Department of Dermatology, University Hospital, Tuebingen, GermanySearch for more papers by this author First published: 25 December 2001 https://doi.org/10.1046/j.1365-4362.1999.00832.xCitations: 58 Martin Braddock, bsc, ph d, Wound Healing and Tissue Regeneration Programme, Glaxo–Wellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UKDrug namesBecaplermin, recombinant human PDGF BB: Regranexautologous platelet releasate: Procuren Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume38, Issue11November 1999Pages 808-817 RelatedInformation